文献速递脑血管病

REVASCAT试验:24小时血管通畅性与临床结局及梗死体积的关系

Vessel Patency at 24 Hours and Its Relationship With Clinical Outcomes and Infarct Volume in REVASCAT Trial (Randomized Trial of Revascularization With Solitaire FR Device Versus Best Medical Therapy in the Treatment of Acute Stroke Due to Anterior Circulation Large Vessel Occlusion Presenting Within Eight Hours of Symptom Onset).
PubMed 文献 · Stroke · 2017-03-14

REVASCAT试验预设次要终点分析显示,取栓组24小时完全再通率70.5%高于对照组的22.3%(P<0.001)。完全再通与取栓组(aOR 4.5,95%CI 1.9-10.9)和对照组(aOR 2.7,95%CI 1.0-6.7)的临床结局改善相关,任何类型再通均与更小梗死体积相关。

要点

  • 取栓组24小时完全再通率70.5%,显著高于对照组22.3%。
  • 完全再通是两治疗组临床结局改善的强预测因素。
  • 任何类型再通均与两治疗组更小梗死体积相关。

核心结论

  • 24小时完全再通是良好临床结局的强预测因素,任何类型再通均减少梗死体积。

研究设计与样本

  • REVASCAT随机试验预设次要终点分析,取栓组95/103例、对照组94/103例完成24小时血管状态评估。
  • 24小时血管状态由独立核心实验室按改良动脉闭塞病变分类评估,基于CTA/MRA(94.2%/5.8%)。
  • 24小时梗死体积通过CT评估,完全再通定义为改良动脉闭塞病变3级。

主要发现

  • 取栓组完全再通率70.5%,对照组22.3%(P<0.001)。
  • 颈内动脉末端、M1及串联闭塞的完全再通率组间差异显著(均P<0.001),M2闭塞无显著差异。
  • 取栓组63例术后mTICI 2b/3患者中2例(3.1%)24小时出现动脉再闭塞(改良动脉闭塞病变0/1级)。
  • 完全再通与取栓组结局改善相关(aOR 4.5,95%CI 1.9-10.9),也与对照组相关(aOR 2.7,95%CI 1.0-6.7)。
  • 再通(改良动脉闭塞病变2/3级)与两治疗组更小梗死体积相关。

关键数值与推荐

  • 完全再通定义为24小时改良动脉闭塞病变分级3级。
  • 再通定义为改良动脉闭塞病变分级2/3级。

临床怎么用

  • 取栓术后应关注24小时血管通畅状态,完全再通者预后更好。
  • 无论取栓还是药物治疗,实现再通有助于缩小梗死体积。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Higher rates of target vessel patency at 24 hours were noted in the thrombectomy group compared with control group in recent randomized trials. As a prespecified secondary end point, we aimed to assess 24-hour revascularization rates by treatment groups and occlusion site as they related to clinical outcome and 24-hour infarct volume in REVASCAT (Randomized Trial of Revascularization With Solitaire FR Device Versus Best Medical Therapy in the Treatment of Acute Stroke Due to Anterior Circulation Large Vessel Occlusion Presenting Within Eight Hours of Symptom Onset). METHODS: Independent core laboratory adjudicated vessel status according to modified arterial occlusive lesion classification at 24 hours on computed tomographic/magnetic resonance (94.2%/5.8%) angiography and 24-hour infarct volume on computed tomography were studied (95/103 patients in the thrombectomy group versus 94/103 in the control group, respectively). Complete revascularization was defined as modified arterial occlusive lesion grade 3. Its effect on clinical outcome was analyzed by ordinal logistic regression. RESULTS: Complete revascularization was achieved in 70.5% of the solitaire group and in 22.3% of the control group (P<0.001). Significant differences in complete revascularization rates were found for terminus internal carotid artery, M1, and tandem occlusions (all P<0.001) but not for M2 occlusions. In the thrombectomy group, 2 out of 63 patients (3.1%) with modified Thrombolysis in Cerebral Infarction 2b/3 after thrombectomy showed arterial reocclusion (modified arterial occlusive lesion grade 0/1) at 24 hours. Complete revascularization was associated with improved outcome in both thrombectomy (adjusted odds ratio, 4.5; 95% confidence interval, 1.9-10.9) and control groups (adjusted odds ratio, 2.7; 95% confidence interval, 1.0-6.7). Revascularization (modified arterial occlusive lesion grade 2/3) was associated with smaller infarct volumes in either treatment arm. CONCLUSIONS: Complete revascularization at 24 hours is a powerful predictor of favorable clinical outcome, whereas revascularization of any type results in reduced infarct volume in both thrombectomy and control groups. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01692379.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Millán M, Remollo S, Quesada H, et al. Vessel Patency at 24 Hours and Its Relationship With Clinical Outcomes and Infarct Volume in REVASCAT Trial (Randomized Trial of Revascularization With Solitaire FR Device Versus Best Medical Therapy in the Treatment of Acute Stroke Due to Anterior Circulation Large Vessel Occlusion Presenting Within Eight Hours of Symptom Onset). Stroke. 2017. PMID: 28292867. doi:10.1161/STROKEAHA.116.015455

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。